Details:
The gross proceeds will be used to advance Bone Therapeutics’ lead orthopedic asset, ALLOB, through mid-stage clinical development and will also support the acceleration of the development of the new iMSC cell and gene therapy platform.
Lead Product(s): Allogeneic Osteoblastic Cells
Therapeutic Area: Musculoskeletal Product Name: Allob
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $3.7 million Upfront Cash: Undisclosed
Deal Type: Private Placement December 03, 2021
Details:
The ALLOB Tibial Fracture Phase IIb study is a randomized, double-blind, placebo-controlled study. In this study, the potential of ALLOB to accelerate fracture healing and prevent late-stage complications in patients with difficult fractures in the shinbone (tibia).
Lead Product(s): Allogeneic Osteoblastic Cells
Therapeutic Area: Musculoskeletal Product Name: Allob
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2021